title: Type I Interferon Receptor Expression in Human Pancreatic and Periampullary Cancer Tissue.
abstract: OBJECTIVE
  Interferons (IFNs) have several anticancer mechanisms. A number of clinical trials have been conducted regarding adjuvant IFN-α therapy in pancreatic cancer. Type I IFNs exert their effect via the type I IFN receptor (IFNAR-1, IFNAR-2c). The aims of the present study were to determine the type I IFN receptor expression in pancreatic and periampullary cancer tissues and to study its relation with clinicopathological factors.
  
  
  METHODS
  Receptor expression was determined by immunohistochemistry in paraffin-embedded cancer tissue of 47 pancreatic and 54 periampullary cancer patients.
  
  
  RESULTS
  The results demonstrated that 91.5% of the pancreatic tumors and 88.9% of the periampullary tumors showed expression of IFNAR-1, of which 23.4% and 13.0% were strongly positive, respectively. Regarding IFNAR-2c expression, 68.1% of the pancreatic tumors and 68.5% of the periampullary tumors were positive, of which 4.3% of the pancreatic tumors and none of the periampullary tumors had a strong expression. No statistically significant associations were found between type I IFN receptor expression and clinicopathological factors or survival.
  
  
  CONCLUSIONS
  Type I IFN receptors are expressed in pancreatic and periampullary cancer tissues although with great intertumoral and intratumoral variability. A small proportion of both tumors showed a strong expression of the IFNAR-1; only a very small percentage of the pancreatic tumors showed strong expression of the IFNAR-2c.
authors: From the *Department of Surgery and †Department of Internal Medicine, Division of Endocrinology, Erasmus Medical Centre, Rotterdam, The Netherlands; ‡US Innovation Center, Specialty Medicine, Global Medical Affairs, Bayer Healthcare Pharmaceuticals, San Francisco, CA; and §Department of Pathology, Erasmus Medical Centre, Rotterdam, The Netherlands.
authors: Stephanie
authors: S
authors: Booy
authors: Leo J
authors: LJ
authors: Hofland
authors: A Marlijn
authors: AM
authors: Waaijers
authors: Ed
authors: E
authors: Croze
authors: Peter M
authors: PM
authors: van Koetsveld
authors: Lisette
authors: L
authors: de Vogel
authors: Katharina
authors: K
authors: Biermann
authors: Casper H J
authors: CH
authors: van Eijck
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014670:Ampulla of Vater / Q000737:chemistry* / Q000473:pathology / Q000601:surgery; D014408:Biomarkers, Tumor / Q000032:analysis*; D003138:Common Bile Duct Neoplasms / Q000737:chemistry* / Q000401:mortality / Q000473:pathology / Q000628:therapy; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010190:Pancreatic Neoplasms / Q000737:chemistry* / Q000401:mortality / Q000473:pathology / Q000628:therapy; D011237:Predictive Value of Tests; D016016:Proportional Hazards Models; D053633:Receptor, Interferon alpha-beta / Q000032:analysis*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D014408:Biomarkers, Tumor; C507964:IFNAR1 protein, human; C508033:IFNAR2 protein, human; D053633:Receptor, Interferon alpha-beta